Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial
2 March 2022
ASX ANNOUNCEMENT
Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial
Medical Developments International Ltd (ASX: MVP) announces that the US Food and Drug Administration (FDA) has unconditionally lifted the agency’s clinical hold on Penthrox. This means that MVP can immediately begin preparing for its Phase III US clinical trial. As anticipated, the trial will be conducted on a targeted trauma and associated pain patient group. We expect that the 2-year trial will commence recruitment in late 2022.
For further details please click on the following for the full announcement – ASX Announcement – Green Whistle gets the Green Light